<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657163</url>
  </required_header>
  <id_info>
    <org_study_id>0300501</org_study_id>
    <secondary_id>French PHRC</secondary_id>
    <nct_id>NCT00657163</nct_id>
  </id_info>
  <brief_title>Fluoxetine on Motor Rehabilitation After Ischemic Stroke</brief_title>
  <acronym>FLAME</acronym>
  <official_title>Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recovery from stroke is a major process and, except for acute intravenous thrombolysis, no
      treatment able to enhance recovery has yet been validated. Some drugs may have a positive
      effect when combined with physical rehabilitation. Previous studies have shown a potential
      effect of catecholaminergic drugs on cerebral plasticity of stroke patients. In 2001, our
      group has demonstrated in a small group of stroke patients (n=8) that a single dose of
      fluoxetine (Selective Serotonin Reuptake Inhibitor - SSRI) improved motor performance and
      modulated cerebral plasticity. We conducted a phase IIb prospective, double-blind,
      randomized, placebo controlled study to assess the effect of a daily treatment with fluoxetin
      (20 mg) on motor performance in patients with mild to severe motor deficit after ischemic
      stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We project to include in the study a maximum of 168 patients with a recent (5 to 10 days)
      ischemic stroke and unilateral motor deficit in order to obtain 100 completed patients. Nine
      stroke centers in France are involved.

      Each patient will receive daily, during three months, 20 mg of fluoxetin or placebo.

      Patients will be evaluated at inclusion, day 30, M3 (3 months), M12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression in the Fugl-Meyer Motor Scale</measure>
    <time_frame>M3 (3 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Stroke Scale</measure>
    <time_frame>M12 (12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH stroke scale</measure>
    <time_frame>M3 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS depression scale</measure>
    <time_frame>M3 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin scale</measure>
    <time_frame>M3 and M12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>M3 and M12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Motor Impairment</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluoxetine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluoxetine</intervention_name>
    <description>fluoxetine per os 20 mg daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>PROZAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo per os daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged from 18 to 85

          -  No motor relapse from a previous stroke

          -  Inclusion from day 5 to day 10 after stroke

          -  Ischemic stroke with unilateral motor deficit

          -  Motor NIHSS ≥ 5 on the affected side of the body

          -  NIHSS &lt; 20

          -  Fugl Meyer Motor Scale &lt;55

          -  Modified Rankin Scale between 1 and 5

          -  Informed consent obtained from the subject or a member of his family

        Exclusion Criteria:

          -  Pregnant or breast-feeding woman

          -  Woman able to procreate without valid contraception

          -  Subject protected by law

          -  Concomitant disease with unfavourable prognosis within 1 year

          -  Drug addiction

          -  Allergy to fluoxetine

          -  Hepatic failure (TGO and TGP &gt;2N)

          -  Permanent Renal failure (Creatinin &gt;180micromol/l)

          -  Patients treated by tricyclic antidepressant, selective serotonin reuptake inhibitor,
             monoamine oxidase inhibitor (IMAO), and neuroleptics in the past month

          -  Depression requiring pharmacological treatment

          -  Previous stroke with motor relapse

          -  Fugl Meyer Motor Scale &gt; 55

          -  Modified Rankin Scale = 0 or 6

          -  Patients needing carotid surgery within 3 months

          -  Aphasia preventing correct evaluation of motor and depression scales.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Chollet, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital René Dubos</name>
      <address>
        <city>Cergy-Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38048</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Sainte Anne</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001 Dec;50(6):718-29.</citation>
    <PMID>11761469</PMID>
  </reference>
  <reference>
    <citation>Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996 Jul;27(7):1211-4.</citation>
    <PMID>8685930</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>September 15, 2011</last_update_submitted>
  <last_update_submitted_qc>September 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke recovery</keyword>
  <keyword>Pharmacological modulation</keyword>
  <keyword>Selective Serotonin Reuptake Inhibitor (SSRI)</keyword>
  <keyword>Fluoxetine</keyword>
  <keyword>Brain plasticity</keyword>
  <keyword>Ischemic Stroke and Motor impairment</keyword>
  <keyword>Modulation of recovery and cerebral plasticity by Fluoxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

